$NRIX
Nurix Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000154959524000131 Filed on October 11, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $12.59M
YoY Change -31.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.72M
YoY Change 10.34%
% of Gross Profit
Research & Development $55.48M
YoY Change 15.93%
% of Gross Profit
Depreciation & Amortization $2.394M
YoY Change 22.77%
% of Gross Profit
Operating Expenses $67.20M
YoY Change 14.91%
Operating Profit -$54.61M
YoY Change 36.49%
Interest Expense $5.737M
YoY Change 89.34%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$48.87M
YoY Change 32.16%
Income Tax $82.00K
% Of Pretax Income
Net Earnings -$48.96M
YoY Change 32.38%
Net Earnings / Revenue -388.91%
Basic Earnings Per Share -$0.67
Diluted Earnings Per Share -$0.67
COMMON SHARES
Basic Shares Outstanding 70.84M shares 64.41M shares
Diluted Shares Outstanding 72.78M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $448.1M
YoY Change 73.06%
Cash & Equivalents $110.0M $99.04M
Short-Term Investments $349.0M
Other Short-Term Assets $7.991M
YoY Change 12.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $619.4M $456.0M
YoY Change 109.6% 70.2%
LONG-TERM ASSETS
Property, Plant & Equipment $17.76M $17.07M
YoY Change 5.65% 2.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.472M
YoY Change -4.32%
Other Assets $3.159M $3.032M
YoY Change -17.37% -21.35%
Total Long-Term Assets $49.96M $57.56M
YoY Change -16.87% 43.01%
TOTAL ASSETS
Total Short-Term Assets $619.4M $456.0M
Total Long-Term Assets $49.96M $57.56M
Total Assets $669.3M $513.6M
YoY Change 88.23% 66.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.48M $3.918M
YoY Change 79.38% 79.15%
Accrued Expenses $34.38M
YoY Change 25.94%
Deferred Revenue $38.36M $48.00M
YoY Change -20.24% 49.82%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $95.85M $86.30M
YoY Change 10.23% 40.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $50.45M
YoY Change 291.07%
Total Long-Term Liabilities $50.45M
YoY Change 291.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $95.85M $86.30M
Total Long-Term Liabilities $50.45M
Total Liabilities $142.4M $136.7M
YoY Change -8.22% 83.85%
SHAREHOLDERS EQUITY
Retained Earnings -$738.8M -$680.2M
YoY Change 35.51% 35.17%
Common Stock $1.266B $1.057B
YoY Change 69.57% 43.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $527.0M $376.9M
YoY Change
Total Liabilities & Shareholders Equity $669.3M $513.6M
YoY Change 88.23% 66.65%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$48.96M
YoY Change 32.38%
Depreciation, Depletion And Amortization $2.394M
YoY Change 22.77%
Cash From Operating Activities -$42.18M
YoY Change 2.55%
INVESTING ACTIVITIES
Capital Expenditures $2.347M
YoY Change -4.59%
Acquisitions
YoY Change
Other Investing Activities -$18.99M
YoY Change -175.28%
Cash From Investing Activities -$21.34M
YoY Change -193.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 45.77M
YoY Change 2592.35%
NET CHANGE
Cash From Operating Activities -42.18M
Cash From Investing Activities -21.34M
Cash From Financing Activities 45.77M
Net Change In Cash -17.75M
YoY Change 6.52%
FREE CASH FLOW
Cash From Operating Activities -$42.18M
Capital Expenditures $2.347M
Free Cash Flow -$44.52M
YoY Change 2.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001549595
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line1
EntityAddressAddressLine1
1700 Owens Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 205
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
660-5320
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
NRIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27083000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31142000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17069000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16808000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3032000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3823000 usd
CY2023Q4 us-gaap Assets
Assets
355598000 usd
CY2024Q3 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
27828000 usd
CY2023Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
24970000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
155105000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
746299000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-655000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-680220000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-545200000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
376856000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
200493000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
513600000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1056665000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355598000 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48718552 shares
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55481000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47856000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
154408000 usd
dei Entity Registrant Name
EntityRegistrantName
NURIX THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0838048
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54627000 usd
CY2024Q3 us-gaap Assets
Assets
513600000 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48718552 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
67000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139435000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11718000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10623000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
67199000 usd
us-gaap Operating Expenses
OperatingExpenses
171557000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32122000 usd
us-gaap Operating Expenses
OperatingExpenses
189635000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35227000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
3030000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
13612000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36982000 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67083523 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67083523 shares
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
344000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12588000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18467000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41265000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61828000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-40012000 usd
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
5737000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-134758000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101992000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
82000 usd
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
9472000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6553000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7489000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
47997000 usd
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48874000 usd
dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
262000 usd
dei Entity Shell Company
EntityShellCompany
false
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70836282 shares
CY2024Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
349008000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
233281000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7991000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
7421000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3918000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
58479000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-54611000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-148370000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-109729000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-48956000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36982000 usd
us-gaap Net Income Loss
NetIncomeLoss
-135020000 usd
us-gaap Net Income Loss
NetIncomeLoss
-101992000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72779381 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72779381 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54390859 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54390859 shares
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6401000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
48098000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
86296000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
7737000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7595000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
456043000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
295503000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
86958000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20590000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23125000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54227491 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-48956000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36982000 usd
us-gaap Net Income Loss
NetIncomeLoss
-135020000 usd
us-gaap Net Income Loss
NetIncomeLoss
-101992000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
479000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
999000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3091000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36307000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-134021000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
303696000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000 usd
CY2023Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
31000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1453000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8505000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1072000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40733000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
274052000 usd
CY2023Q2 nrix Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
148497 shares
CY2023Q2 nrix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000 usd
CY2023Q2 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
31000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8746000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1344000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24277000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
259921000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99044000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
29858000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45022000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
136744000 usd
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63384174 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63384174 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54227491 shares
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
675000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48477000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98901000 usd
CY2023Q3 nrix Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
568863 shares
CY2023Q3 nrix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
927000 usd
CY2023Q3 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
29000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
776000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8470000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
675000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36982000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
233817000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
200493000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
355000 usd
CY2024Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
21000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1269000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7823000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
305000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-41518000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
168748000 usd
CY2024Q2 nrix Adjustments To Additional Paid In Capital Stock And Warrants Issued Offering Costs
AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedOfferingCosts
12518000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1684000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
216000 usd
CY2024Q2 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
12000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8847000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
215000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44546000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
370693000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
920000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3035000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
863000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8762000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
479000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-48956000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
376856000 usd
us-gaap Net Income Loss
NetIncomeLoss
-135020000 usd
us-gaap Net Income Loss
NetIncomeLoss
-101992000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6769000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5599000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
25421000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
25649000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7795000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3453000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-544000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5356000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4298000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-286000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-767000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2556000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2376000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3036000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15265000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31327000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4768000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4940000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2792000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
48000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-123833000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108054000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
409738000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
157941000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
300010000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
246431000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7168000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5816000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-116896000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
82674000 usd
nrix Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
188732000 usd
nrix Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
90691000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
3606000 usd
nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
981000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2132000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2229000 usd
nrix Payments For Repurchase Of Stock Options
PaymentsForRepurchaseOfStockOptions
15000 usd
nrix Payments For Repurchase Of Stock Options
PaymentsForRepurchaseOfStockOptions
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
285146000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3210000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
44417000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22170000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55528000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65375000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99945000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43205000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
483000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1054000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1297000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
11000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
72000 usd
nrix Deferred Issuance Costs Included In Accrued Expenses And Other Liabilities
DeferredIssuanceCostsIncludedInAccruedExpensesAndOtherLiabilities
156000 usd
nrix Deferred Issuance Costs Included In Accrued Expenses And Other Liabilities
DeferredIssuanceCostsIncludedInAccruedExpensesAndOtherLiabilities
0 usd
nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
242000 usd
nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
0 usd
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
33000 usd
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
91000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99044000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42304000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99945000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43205000 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
448100000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-680200000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company also makes certain commencement date estimates for its leases, including the incremental borrowing rate, the expected lease term and the fair value of the leased asset. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. Refer to Note 3 for more information regarding the estimates related to revenue recognition.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s marketable securities consist of debt securities issued by the U.S. federal government or state and local governments. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds. During the periods presented, the Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</span></div>
CY2019Q2 nrix Number Of Drug Candidates
NumberOfDrugCandidates
1 candidate
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
49171000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
43057000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32102000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26249000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17069000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16808000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11705000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15303000 usd
CY2024Q3 nrix Accrued Clinical Contract Research And Lab Supplies
AccruedClinicalContractResearchAndLabSupplies
12719000 usd
CY2023Q4 nrix Accrued Clinical Contract Research And Lab Supplies
AccruedClinicalContractResearchAndLabSupplies
7131000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1836000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1755000 usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
906000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
30000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
662000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
751000 usd
CY2024Q3 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
27828000 usd
CY2023Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
24970000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 position
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 position
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 usd
nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2024Q3 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2023Q3 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2024Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
57902 sqft
CY2024Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2021Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
19320 sqft
CY2024Q1 nrix Operating Lease Rent Payable Adjustment Per Month
OperatingLeaseRentPayableAdjustmentPerMonth
100000 usd
CY2022Q1 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
46434 sqft
CY2023Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
50094 sqft
CY2023Q3 nrix Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
2 option
CY2023Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2024Q3 us-gaap Variable Lease Payment
VariableLeasePayment
1800000 usd
us-gaap Variable Lease Payment
VariableLeasePayment
5200000 usd
CY2023Q3 us-gaap Variable Lease Payment
VariableLeasePayment
1600000 usd
us-gaap Variable Lease Payment
VariableLeasePayment
4600000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
2200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
6800000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
4500000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
6177000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
4182000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
nrix Common Stock Voting Rights For Shareholders
CommonStockVotingRightsForShareholders
1 vote
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21656407 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18828875 shares
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
55800000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2024Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000 usd
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1000000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
82000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
262000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-48956000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36982000 usd
us-gaap Net Income Loss
NetIncomeLoss
-135020000 usd
us-gaap Net Income Loss
NetIncomeLoss
-101992000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72779381 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72779381 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54390859 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54390859 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63384174 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63384174 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54227491 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54227491 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12011257 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10132980 shares
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001549595-24-000131-index-headers.html Edgar Link pending
0001549595-24-000131-index.html Edgar Link pending
0001549595-24-000131.txt Edgar Link pending
0001549595-24-000131-xbrl.zip Edgar Link pending
ex101_nurixare26amendmentn.htm Edgar Link pending
ex102_nurixare26amendmentn.htm Edgar Link pending
ex103_nurixare26amendmentn.htm Edgar Link pending
ex104_nurixare19amendmentn.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
image_01.jpg Edgar Link pending
image_02.jpg Edgar Link pending
image_03.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nrix-20240831.htm Edgar Link pending
nrix-20240831.xsd Edgar Link pending
nrix-20240831x10qxex311.htm Edgar Link pending
nrix-20240831x10qxex312.htm Edgar Link pending
nrix-20240831x10qxex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
nrix-20240831_lab.xml Edgar Link unprocessable
nrix-20240831_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nrix-20240831_def.xml Edgar Link unprocessable
nrix-20240831_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
nrix-20240831_pre.xml Edgar Link unprocessable